(Q36407379)

English

Sorafenib

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

1 reference

Europe PubMed Central

Sorafenib. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

author name string

Brian I Rini

1

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

language of work or name

0 references

publication date

1 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

453-461

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Raf: a strategic target for therapeutic development against cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

BAY 43-9006: preclinical data

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Discovery of a novel Raf kinase inhibitor

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Identifiers

10.1517/14656566.7.4.453

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

release_thsf5qaehbdsdhfg4h2h2t5ocm

1 reference

https://api.fatcat.wiki/v0/release/thsf5qaehbdsdhfg4h2h2t5ocm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36407379&oldid=1838781387"